Gilead Sciences Inc
Change company Symbol lookup
Select an option...
GILD Gilead Sciences Inc
LAD Lithia Motors Inc
SBUX Starbucks Corp
HYLN Hyliion Holdings Corp
NIO NIO Inc
F Ford Motor Co
GM General Motors Co
PG Procter & Gamble Co
GE General Electric Co
DEO Diageo PLC
Go

Health Care : Biotechnology | Large Cap Value
Company profile

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost and Vitekta. Its products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Sovaldi, Viread and Hepsera. It offers Zydelig to patients with hematology/oncology diseases. Its products for patients with various cardiovascular diseases include Letairis, Ranexa and Lexiscan. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. It had operations in more than 30 countries, as of December 31, 2016.

Closing Price
$58.15
Day's Change
-0.38 (-0.65%)
Bid
--
Ask
--
B/A Size
--
Day's High
58.58
Day's Low
57.18
Volume
(Average)
Volume:
11,871,686

10-day average volume:
12,568,205
11,871,686

SHAREHOLDER ALERT: WeissLaw LLP Investigates Immunomedics, Inc.

6:57 pm ET September 14, 2020 (PR Newswire) Print

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Immunomedics, Inc. ("IMMU" or the "Company") (NASDAQ: IMMU) in connection with the proposed acquisition of the Company by Gilead Sciences, Inc. ("Gilead") (NASDAQ: GILD). Under the terms of the acquisition agreement, which is structured as a tender offer, the Company's shareholders will receive $88.00 in cash for each share of IMMU common stock that they own.

https://mma.prnewswire.com/media/743985/WeissLaw_Logo_Stacked_LowerCase_color_2_Logo.jpg

If you own IMMU shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website:

https://www.weisslawllp.com/immunomedics-inc-ii/

Or please contact:Joshua Rubin, Esq.WeissLaw LLP1500 Broadway, 16th FloorNew York, NY 10036(212) 682-3025 (888) 593-4771stockinfo@weisslawllp.com

WeissLaw is investigating whether IMMU's board acted to maximize shareholder value in agreeing to the proposed transaction, whether the board was fully informed as to the valuation of the proposed acquisition of the Company, and whether all information regarding the valuation of the deal will be fully and fairly disclosed to IMMU shareholders.

Notably, at least one analyst set a price target of $105.00 per IMMU share, or $17.00 above the per-share offer price.

WeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties. We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases. If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at stockinfo@weisslawllp.com

https://c212.net/c/img/favicon.png?sn=DC24435&sd=2020-09-14

View original content to download multimedia:http://www.prnewswire.com/news-releases/shareholder-alert-weisslaw-llp-investigates-immunomedics-inc-301130531.html

SOURCE WeissLaw LLP

https://rt.prnewswire.com/rt.gif?NewsItemId=DC24435&Transmission_Id=202009141857PR_NEWS_USPR_____DC24435&DateId=20200914

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.